Abl knockout differentially affects p130 Crk-associated substrate, vinculin, and paxillin in blood vessels of mice.
Actin polymerization has recently emerged as an important cellular process that regulates smooth muscle contraction. Abelson tyrosine kinase (Abl) has been implicated in the regulation of actin dynamics and force development in vascular smooth muscle. In the present study, the systolic blood pressure was lower in Abl(-/-) knockout mice compared with wild-type mice. The knockout of Abl diminished the tyrosine phosphorylation of p130 Crk-associated substrate (CAS, an adapter protein associated with smooth muscle contraction) in resistance arteries upon stimulation with phenylephrine or angiotensin II. The agonist-elicited enhancement of F-actin-to-G-actin ratios in arteries assessed by fluorescent microscopy was also reduced in Abl(-/-) mice. It has been known that vinculin is a structural protein that links actin filaments to extracellular matrix via transmembrane integrins, whereas paxillin is a signaling protein associated with focal contacts mediating actin cytoskeleton remodeling. The expression of vinculin and paxillin at protein and messenger levels was lower in arterial vessels from Abl knockout mice. However, the agonist-induced increase in myosin phosphorylation was not attenuated in arteries from Abl knockout mice. These results indicate that Abl differentially regulates Crk-associated substrate, vinculin, and paxillin in arterial vessels. The Abl-regulated cellular process and blood pressure are independent of myosin activation in vascular smooth muscle.
Chen
Shu
S
The Center for Cardiovascular Sciences, Albany Medical College, Albany, New York 12208, USA.
Wang
Ruping
R
Li
Qing-Fen
QF
Tang
Dale D
DD
D000199:Actins / Q000378:metabolism; D000818:Animals; D001011:Aorta / Q000502:physiology; D001549:Benzamides; D001794:Blood Pressure / Q000502:physiology; D050719:Crk-Associated Substrate Protein / Q000378:metabolism*; D000068877:Imatinib Mesylate; D008297:Male; D008638:Mesenteric Arteries / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D009131:Muscle, Smooth, Vascular / Q000502:physiology*; D018994:Myosin Light Chains / Q000378:metabolism; D051419:Paxillin / Q000378:metabolism*; D010766:Phosphorylation / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology; D014661:Vasoconstriction / Q000502:physiology*; D016596:Vinculin / Q000378:metabolism*
D000199:Actins; D001549:Benzamides; D050719:Crk-Associated Substrate Protein; D018994:Myosin Light Chains; D051419:Paxillin; D010879:Piperazines; D047428:Protein Kinase Inhibitors; C496062:Pxn protein, mouse; D011743:Pyrimidines; D016596:Vinculin; D000068877:Imatinib Mesylate; D016315:Proto-Oncogene Proteins c-abl